Labcorp Holdings Inc. (BMV:LH)
4,964.73
0.00 (0.00%)
At close: Aug 4, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Diagnostics (Dx) | 10.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diagnostics (Dx) Growth | 8.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drug Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drug Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 11.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Laboratory Services (BLS) | 2.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Laboratory Services (BLS) Growth | 6.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 11.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Other | -927.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 0.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diagnostics (Dx) Operating Earnings | 1.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Diagnostics (Dx) Operating Earnings Growth | 3.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drug Development Operating Earnings | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drug Development Operating Earnings Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -927.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 0.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Laboratory Services (BLS) Operating Earnings | 458.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Laboratory Services (BLS) Operating Earnings Growth | 13.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2013 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2013 - 2019 |
Organic Revenue Growth | 3.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America % Total Revenue | 87.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe % Total Revenue | 9.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geography % Total Revenue | 4.00 |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geography % Total Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|